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The effect of oral mexiletine therapy on ventricular ar•
rhythmias was evaluated in 58 patients in whom con•
ventional drugs had been unsuccessful. Mean daily dose 
ofmexiletine was 652 mg (range 250 to 1,500) and mean 
duration of therapy was 14.4 months (range 0.1 to 34.4). 
Mexiletine was associated with a decrease of 52 % in total 
premature ventricular complexes in 24 hours compared 
with control (6,841 ± 1,053 [SEM] versus 3,248 ± 734, 
P < 0.005) and 19 patients (36.5%) had a greater than 
83% decrease in ventricular ectopic rhythm. The drug 
was discontinued in 6 of these 19 patients because 5 of 
them (26%) experienced side effects after a mean period 
of 29.6 weeks (range 0.83 to 63.2) and sudden death 
occurred in 1 patient (5%); this indicates effective 
suppression of ventricular ectopic rhythm without sig•
nificant side effects in 13 (25 %) of 52 patients during 
long-term therapy. Adjustment of drug dosage to achieve 
therapeutic blood levels resulted in an efficacy on ven•
tricular ectopic rhythm similar to that obtained with the 
Mexiletine is an investigational antiarrhythmic agent that 
has shown promise in initial clinical trials against ventricular 
arrhythmias in heart disease of diverse etiologies (1-3). 
Structurally and electrophysiologically mexiletine resem•
bles lidocaine but it also possesses membrane-stabilizing 
properties characteristic of procainamide and quinidine (4,5). 
The drug has a prolonged pharmacologic half-life and has 
been associated with few serious side effects (6,7). How•
ever, the long-term antiarrhythmic efficacy of mexiletine 
and its effects on cardiac function have not been fully clar•
ified. Therefore, we analyzed the results of oral mexiletine 
therapy in a large group of patients with ventricular ar•
rhythmias treated for an average interval of more than 1 
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maximal tolerated dose. There was no correlation be•
tween drug dose and therapeutic effectiveness. 
Mexiletine was associated with a 48% decrease in ep•
isodes of ventricular tachycardia (345.5 versus 179.3/24 
h) and 5 of 10 patients with a history of cardiac arrest 
remained free of symptomatic ventricular tachyarrhyth•
mias for 14.8 months (range 3.7 to 24.3). In 12 patients 
left ventricular ejection fraction, determined by radio•
nuclide angiography before and during mexiletine ther•
apy, demonstrated no significant change (32 versus 34 % ). 
Adverse effects requiring discontinuation of mexiletine 
occurred in 12 patients (21 %) in the entire group and 
were primarily related to the central nervous system and 
gastrointestinal tract. Mexiletine was effective in a mod•
est proportion of patients in whom conventional antiar•
rhythmic therapy had failed. Ventricular function ap•
peared to be unaffected by the drug and the side effects, 
although relatively frequent, were not serious. 
(J Am Coil Cardiol1985;6:780-4) 
year. In addition, the effects of the agent on ventricular 
function were assessed in a subgroup of these patients. 
Methods 
Patients. The study group consisted of 58 patients (45 
men and 13 women) of average age 59.5 years (range 27 
to 82). Cardiac diagnoses included: coronary heart disease, 
36 patients (62%); cardiomyopathy, 11 patients (19%); val•
vular heart disease, 6 patients (10%) and other diagnoses, 
5 patients (9%). During this evaluation 53 patients (91 %) 
were taking one or more cardiac drugs, including 18 patients 
(31 %) receiving conventional antiarrhythmic agents (Table 
1). The indications for mexiletine therapy were 30 or more 
premature ventricular complexes per hour and complex ven•
tricular ectopic rhythm (multifocal premature ventricular 
complexes, couplets or ventricular tachycardia, defined as 
three or more consecutive premature ventricular complexes 
documented by ambulatory electrocardiographic monitor•
ing). Fifty-three (91%) of the 58 patients had been treated 
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Table 1. Concurrent Cardiovascular Drugs in 53 Patients 
Antiarrhythmic agents 
Digoxin 
Beta-blocking agents 
Diuretic drugs 
Antihypertensive drugs 
Calcium channel blockers 
Total patients 
No. of Patients (%) 
18 (31) 
26 (44.8) 
6 (10.3) 
24 (41.4) 
9 (15.5) 
I (1.7) 
53* 
*Thirty-one patients were taking more than one drug. 
unsuccessfully with one or more conventional antiar•
rhythmic agents (average 2.6 drugs per patient) and 50 of 
the patients (83%) had been treated without success with 
two or more conventional drugs, all of which were discon•
tinued because of adverse reactions or lack of efficacy. Ten 
patients had had one or more episodes of ventricular tachy•
cardia or fibrillation necessitating cardiopulmonary 
resuscitation. 
Mexiletine administration. Mexiletine was adminis•
tered in the form of 100 or 200 mg tablets. The initial dose 
of 100 or 200 mg two or three times per day was progres•
sively increased until the onset of side effects (maximal 500 
mg three times per day), at which time the dose was grad•
ually decreased until side effects resolved. Mexiletine blood 
levels were measured by high pressure gas chromatography 
(8) in 33 of the patients (57%) in whom the drug dose was 
adjusted to achieve a therapeutic plasma level (0.7 to 2.0 
JLg/ml). Administration of mexiletine was approved by the 
Human Studies Committee of the University of California, 
Davis, and all patients gave written informed consent before 
receiving the drug. 
Ambulatory electrocardiography. The efficacy of 
mexiletine was assessed by ambulatory electrocardiographic 
monitoring before and during treatment with the drug. Twenty•
four hour ambulatory electrocardiography was performed at 
least once before mexiletine administration in all patients 
and 27 patients (51 %) were assessed by t\\-,'o or more pre•
treatment ambulatory electrocardiographic studies. Twenty•
four hour ambulatory electrocardiography was performed at 
least once in all patients during mexiletint( therapy and 29 
patients (55%) were assessed by two or more ambulatory 
electrocardiographic evaluations during mexiletine therapy. 
The ambulatory electrocardiograms were analyzed on the 
A vionics Dynamic Cardioelectroscanner, model 660, before 
November 1982. Tracings were analyzed visually and pre•
mature ventricular complexes were hand counted. After No•
vember 1982, ventricular ectopic activity was identified and 
quantitated automatically by the Del Mar Avionics Arrhyth•
mia Analyzer 9020 A. This system has a sensitivity of 
99.1 % and a positive predictive accuracy of 99.9% as as~ 
sessed by the American Heart Association arrhythmia da•
tabase (9). Ventricular ectopic activity was evaluated in 
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terms of frequency of premature ventricular complexes and 
number of episodes of ventricular tachycardia. All electro•
cardiographic tracings were reviewed by a member of the 
Division of Cardiovascular Medicine. 
Efficacy of mexiletine on ventricular ectopic rhythm was 
evaluated for the entire group of patients and separate anal•
ysis was performed in the subgroup in whom mexiletine 
blood levels were obtained. The criterion for antiarrhythmic 
efficacy was an 83% quantitative decrease in premature 
ventricular complexes demonstrated by amb\llatory electro•
cardiography during mexiletine therapy compared with the 
value on pre-drug ambulatory electrocardiography (10,11). 
Clinical assessment. All patients were evaluated by his•
tory and physical examination before beginning mexiletine 
therapy, I to 2 weeks after initiation of treatment and at 
least every 3 months thereafter. The evaluation included 
detailed assessment of drug side effects which were recorded 
and followed up longitudinally. When indicated by side 
effects, drug dosage was adjusted or the drug was discon•
tinued. Twelve lead electrocardiograms were obtained at 
rest before treatment and at least every 3 months and con•
tinuous ambulatory electrocardiography was performed as 
indicated in addition to the minimum of one recording before 
and one during mexiletine treatment. 
Left ventricular function. Radionuclide ventriculog•
raphy by gated blood pool scintigraphy was performed in 
12 randomly selected patients before mexiletine therapy and 
at tpe time of therapeutic blood levels of mexiletine (12). 
Right and left ventricular wall motion was analyzed and left 
ventricular ejection fraction was calculated. 
Statistical analysis. 5tatistical analysis was performed 
by Student's t test for Pflired data to determine differences 
between means of independent observations and by chi•
square test with Yates' correction to determine differences 
between proportions. 
Results 
Mexiletine dose and antiarrhythmic efficacy. The av•
erage dose was 652 mg/day (rapge 250 to 1,500) admin•
istered as a divided dose two or three times daily. Of the 
58 patients in whom mexiletine therapy was initiated, 52 
patients had adequate 24 hour arpbulatory electrocardio•
graphic data for analysis. In this group of 52 patients, the 
maximal tolerated dose of mexiletine was associated with 
a group mean decrease of 52% in the total number of pre•
mature ventricular complexes per 24 hours before mexiletine 
therapy (6,841 ± 1,053 [SEM])-compared with the total 
number during therapy (3,248 ± 734, P < 0.005). For the 
entire group no clear relation existed between the daily dose 
of mexiletine and the decrease of premature ventricular com•
plexes (Fig. 1). Nineteen patients (36.5%) had a greater 
than 83% decrease in premature ventricular complexes on 
this maximal tolerated dose. 
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Figure 1. Relation between the daily dose of mexiletine. and 
reduction of premature ventricular complexes. Dat~ indicate 
mean ± SEM. 
In these 19 patients, the drug required discontinuation 
because of side effects in 5 patients (27%) after a mean 
period of 29.6 weeks (range 0.83 to 63.2) and sudden death 
occurred in one additional patient (5%). Therefore, effective 
antiarrhythmia therapy (> 83% decrease in premature ven•
tricular complexes) without significant side effects was 
achieveQ during long-term treatment with mexiletine in 13 
(25%) of the 52 patients. These patients were treated for a 
mean of 17.8 months (range 3.7 to 34). 
Blood levels and antiarrhythmic efficacy. For those 
patients whose mexiletine blood levels were measured, the 
mean concentration was 0.94 JLg/dl « 0.2 to 2.1). At doses 
greater than 300 mg/day there was little relation between 
dose and blood levels (Fig. 2). In the 33 patients in whom 
therapeutic mexiletine blood levels were measured, the mean 
decrease in premature ventricular complexes per 24 hours 
was 55% (5,732 ± 1,228 versus 2,576 ± 625, p < 0.b25), 
and 13 (39%) of these patients had a greater than 83% 
decrease in premature ventricular complexes. In these 13 
responsive patients, discontinuation of the drug was required 
Figure 2. Relation between daily dose of mexiletine, drug bloQd 
level and efficacy (>83% suppression of premature ventricular 
complexes). 
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because of side effects in 4 patients (35%) and 1 patient 
died suddenly (the same patient in whom sudden death oc•
curred on the maximal tolerated dose of mexiletine noted 
previously). Thus, of33 patients with therapeutic mexiletine 
blood levels, 9 (27%) demonstrated drug efficacy without 
significant side effects. These nine patients were treated for 
a mean of 14.8 months (range 3.7 to 34.4). 
Effect of mexiletine on ventricular tachycardia. The 
effect of mexiletine on ventricular tachycardia, defined by 
three or more consecutive premature ventricular complexes, 
was quantified in the 11 patients who demonstrated one or 
more runs of ventricular tachycardia on ambulatory electro•
cardiography before mexiletine therapy. There was a de•
crease of 48% (range 345.5 to 179.3) in the total number 
of episodes of ventricular tachycardia per 24 hours in this 
group of 11 patients. In six of these the average number of 
episodes of ventricular tachycardia diminished by 100% 
during mexiletine therapy (37.8124 h versus 0.05124 h), 
whereas there was no change in this finding in the other 
five patients. 
Patients with history of cardiac arrest. Of the 10 pa•
tients who had ventricular tachycardia or ventricular fibril•
lation necessitating cardiopulmonary resuscitation before 
mexiletine therapy, the mean decrease in the total number 
of premature ventricular complexes for the group was 58.3% 
after mexiletine treatment. In five patients (50%), there were 
no further episodes of symptomatic ventricular tachyar•
rhythmias on mexiletine therapy during an average interval 
of 14.8 months (range 3.7 to 24.3). In this latter subgroup 
there was an 88% decrease in total premature ventricular 
complexes during mexiletine therapy (334.9/24 h versus 
39.5124 h). Of the other five patients, mexiletine was dis•
continued in one because of side effects, one had no re•
sponse to drug therapy, pne died of congestive heart failure, 
one underwent left ventricular aneurysmectomy and one 
died suddenly (the saine patient noted previously). 
Left ventricular function. RadionucIide ventriculog•
raphy in 12 p~tients before and at the' time of therapeutic 
mexiletine blood levels (me;tn 1.2 JLg/dl, range 0.8 to 2.0) 
demonstrated no signlfica,nt change in left or right ventric•
ular w'all motion or left ventric\llar ejection fraction which 
was 32% (range 13 to 61) before mexiletine therapy and 
34% (range 10 to 63) during therapy (Fig. 3). 
Adverse drug effects: Side effects were noted in 25 
patients (43%). tn 13 (52%) of trem, a moderate decrease 
in dose allowed continued use of mexiletine and in 12 (48%) 
the drug had to be discontinued because of adverse reactions 
that were severe or persisted even after the dose was de•
creased. For all patients with side effects, the mean dose 
of mexiletine was 688 mg/day (300 to 1,2(0) and the mean 
blood level was 0.88 JLg/ml « Q.2 to 1.3). For those pa•
tients in whom side effects caused termination of therapy, 
the mean dose was 800 mg/day (range 300 to 1,2(0) and 
the mean blood level was 0.95 JLg/ml (range 0.8 to 1.2). 
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Figure 3. Left ventricular (L. V,) ejection fraction determined by 
radionuclide angiography in 12 patients before and during mexi•
letine therapy, Mean mexiletine blood level was 1. 2 jLg/dl (range 
0,8 to 2.1). Group mean data are shown by the horizontal bars. 
There was no significant dilference (n.s.) in the data before and 
during mexiletine therapy. 
The most frequent adverse effects were related to the 
gastrointestinal tract and central nervous system (Table 2). 
In the single patient with urinary retention during mexiletine 
therapy, the problem resolved after discontinuation of the 
drug. One patient complained of hair loss while taking mex•
iletine, and hair growth was considered to have returned to 
normal after discontinuation of the drug. Five patients showed 
possible aggravation of ventricular arrhythmias while taking 
mexiletine. In four of these patients there was an increase 
in the total number of premature ventricular complexes per 
24 hours (268.3 before versus 609.3 during therapy). In the 
fifth patient, runs of ventricular tachycardia increased from 
82 to 125124 h in association with mexiletine therapy. Mex•
iletine administration resulted in no significant changes in 
the electrocardiographic QRS axis and no alterations in the 
PR, QRS and QT intervals or in ST segment and T wave 
configurations. 
Table 2. Side Effects of Mexiletine Causing Termination of 
Therapy in 12 Patients 
Side Effect 
Gastrointestinal 
Nausea and vomiting 
Indigestion 
Central nervous system 
Memory loss 
Ataxia 
Dizziness 
Genitourinary 
Urinary retention 
Skin 
Hair loss 
Total 
No. of 
Patients 
7 
3 
12 
5 
2 
Percent of Entire 
Study Group 
(n = 58) 
12.1 
5.2 
1.7 
1.7 
20.7 
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Discussion 
This study demonstrated long-term efficacy and absence 
of significant side effects with mexiletine in the treatment 
of ventricular arrhythmias in 25% of patients with cardiac 
disease of diverse etiologies, more than 90% of whom had 
been unsuccessfully treated with conventional antiar•
rhythmic drugs. Therapeutic efficacy obtained by the max•
imal tolerated dose of mexiletine was similar to that asso•
ciated with dosage given according to blood levels. 
Furthermore, in the small subgroup of patients studied by 
radionuclide ventriculography, mexiletine produced no sig•
nificant alteration of ventricular function. 
Therapeutic effectiveness. The criterion selected as an 
indication of antiarrhythmic efficacy of mexiletine therapy 
was an 83% decrease in premature ventricular complexes, 
as described by Morganroth et al. (11), a value intended to 
confirm drug effect as opposed to spontaneous variability 
of ventricular ectopic rhythm (10). Although 36% of our 
patients had an 83% decrease in total premature ventricular 
complexes during mexiletine therapy, the average decrease 
in the entire group was 53%. No correlation existed between 
drug dose and therapeutic effectiveness. It is emphasized 
that this therapeutic result by mexiletine was effected in a 
patient group of which almost all subjects had been unsuc•
cessfully treated with one or more conventional antiar•
rhythmic agents; the average number of drugs unsuccess•
fully used before mexiletine administration was 2.6 per patient. 
Comparison with previous studies. Our results are 
comparable with those of Podrid and Lown (7), who dem•
onstrated long-term efficacy of mexiletine in 34% of patients 
treated for chronic ventricular ectopic rhythms. Others have 
shown efficacy of mexiletine treatment in more than 50% 
of patients ( 1-3,13, 14). Furthermore, mexiletine has shown 
results comparable with those of quinidine (15), procain•
amide (16) and disopyramide (17) in the treatment of ven•
tricular arrhythmias in ambulatory patients. 
The effect of mexiletine in patients with recurrent ven•
tricular tachycardia has been variable. DiMarco et al. (18) 
reported suppression of episodic ventricular tachycardia in 
a majority of patients with this finding treated with mexi•
letine, but of the 15 patients studied by Heger et al. (19), 
only 4 responded to the drug. Our results in this subgroup 
of patients are intermediate to these previous studies, with 
6 of 11 patients showing virtual abolition of episodes of 
ventricular tachycardia and 5 patients having no response. 
Five of our II patients who survived cardiac arrest due to 
ventricular tachyarrhythmias had no further symptomatic 
ventricular arrhythmias on mexiletine for an average interval 
of 14.8 months. More extensive studies, including a large 
multicenter trial (20,21) assessing the efficacy of mexiletine 
for prophylaxis against sudden death, have indicated 
suppression of premature ventricular complexes but no ef•
fect on sudden death. However, these data pertain exclu•
sively to high risk postmyocardial infarction patients. 
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Discrepancies in the frequency of success with mexiletine 
among current studies can be attributed to a number of 
factors, including the type of arrhythmia (premature ven•
tricular complexes or ventricular tachycardia), criteria of 
efficacy, dosage, severity of the underlying cardiac disease, 
method of selecting patients and duration of study. Our 
patients were resistant to prior therapy and, as indicated by 
radionuclide ventriculography in randomly selected pa•
tients, included those with significant impairment of left 
ventricular function. Furthermore, earlier studies have not 
generally employed the stringent criterion of 83% premature 
ventricular complex suppression as an indication of efficacy. 
Hemodynamic studies. Limited previous hemody•
namic evaluations of mexiletine have been inconsistent, as 
determined by invasive and noninvasive studies, which have 
demonstrated either no cardiac depressant effects (22,23) 
or a modest reduction of ventricular function of lesser degree 
than that ptoduced by disopyramide but greater than that 
produced by lidocaine (24). Our findings provide the first 
data regarding the effects of mexiletine on ventricular func•
tion evaluated by radionuclide ventriculography. These re•
sults are of interest because no deleterious effects of the 
drug were evident in a group of patients with significant 
impairment of left ventricular functiori, as reflected by a 
group mean left ventricular ejection fraction of 32% in 12 
patients, of whom 6 had an ejection fraction of less than 
30% (range 13 to 23%). Ejection fraction decreased no more 
than 3% (absolute value) in any patient after mexiletine 
administration. 
Adverse reactions. Major adverse reactions t~ mexi•
letine in out patients, as has been reported previously, were 
relatively frequent (21 %), were largely related to the gas•
trointestinal tract and central nervous system and were not 
serious (3,6,7). As anticipated in a lidocaine-like agent, no 
significant alterations were evident in intrinsic cardIac pace•
maker function or atrioventricular and intraventricular con•
duction, as reflected in the scalat electrocardiogram. 
Conclusion. Mexiletine demonstrated potential as suc•
cessful therapy against resistant ventricular ectopic rhythm 
in a modest proportion of patients with no serious adverse 
reactions over a prolonged interval. Of particular note was 
its lack of deleterious effects on cardiac performance in 
patients with serious impairment of left ventricular function. 
These findings indicate that rhexiletine may be a useful 
therapeutic agent for the management of ventricular ar•
rhythmias in selected patients. 
We are indebted to James Foerster, MD for his contribution to this work 
and to Della Wilkin and Elaine Holt for their expert secretarial assistance. 
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